Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings, partly because their firms often seek other business from the same companies they cover.
Luckily for you, we at StockStory have no conflicts of interest - our sole job is to help you find genuinely promising companies. Keeping that in mind, here is one stock likely to meet or exceed Wall Street’s lofty expectations and two where consensus estimates seem disconnected from reality.
Two Stocks to Sell:
Genuine Parts (GPC)
Consensus Price Target: $132.43 (29.2% implied return)
Largely targeting the professional customer, Genuine Parts (NYSE: GPC) sells auto and industrial parts such as batteries, belts, bearings, and machine fluids.
Why Do We Pass on GPC?
- Annual sales growth of 3.1% over the last three years lagged behind its consumer retail peers as its large revenue base made it difficult to generate incremental demand
- Disappointing same-store sales over the past two years show customers aren’t responding well to its product selection and store experience
- Operating margin of 4.5% falls short of the industry average, and the smaller profit dollars make it harder to react to unexpected market developments
At $102.49 per share, Genuine Parts trades at 12.5x forward P/E. Check out our free in-depth research report to learn more about why GPC doesn’t pass our bar.
Artivion (AORT)
Consensus Price Target: $42 (105% implied return)
Formerly known as CryoLife until its 2022 rebranding, Artivion (NYSE: AORT) develops and manufactures medical devices and preserves human tissues used in cardiac and vascular surgical procedures for patients with aortic disease.
Why Are We Hesitant About AORT?
- Subscale operations are evident in its revenue base of $458.7 million, meaning it has fewer distribution channels than its larger rivals
- Low free cash flow margin of -0.7% for the last five years gives it little breathing room, constraining its ability to self-fund growth or return capital to shareholders
- Below-average returns on capital indicate management struggled to find compelling investment opportunities
Artivion is trading at $20.49 per share, or 40.3x forward P/E. Read our free research report to see why you should think twice about including AORT in your portfolio.
One Stock to Watch:
Nasdaq (NDAQ)
Consensus Price Target: $106.53 (22.2% implied return)
Originally founded in 1971 as the world's first electronic stock market, Nasdaq (NASDAQ: NDAQ) operates global exchanges and provides technology, data, and corporate services that help companies, investors, and financial institutions navigate capital markets.
Why Is NDAQ on Our Radar?
- Impressive 15% annual revenue growth over the last two years indicates it’s winning market share this cycle
- Earnings per share have outperformed the peer group average over the last two years, increasing by 14.8% annually
- Stellar return on equity showcases management’s ability to surface highly profitable business ventures
Nasdaq’s stock price of $87.20 implies a valuation ratio of 21.5x forward P/E. Is now the time to initiate a position? Find out in our full research report, it’s free.
Stocks We Like Even More
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI is taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662%. AppLovin before it ran 753%. Nvidia before it ran 1,178%. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.
